Cambridge, MA and Salisbury, UK, March 8, 2024–(BUSINESS WIRE)–CalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of oral small molecule protease inhibitors. Today, we announced the acceptance of multiple abstracts. The 2024 HAEi Regional Conference will be held from March 15th to 17th in Panama City, Panama. KalVista is a silver level sponsor of this conference. The presentation is as follows:
-
Relationship between time to on-demand treatment and quality of life during hereditary angioedema attacks: Sandra Christiansen, Timothy Craig, Maeve O’Connor, Cristine Radojicic, Julie Ulloa, Sherry Danese, Vibha Desai, Tomas Andriotti, Paul Audhya, Paula Busse.Results were shared as an oral presentation as part of the summary oral presentation: Saturday Session 1, March 16th at 9:15am ET in the Magnolia Room
-
Anxiety associated with on-demand treatment for hereditary angioedema (HAE) attacks: James Wenner, Christine Radozic, Julie Ulloa, Shelley Danese, Viva Desai, Paul Audia, sandra christiansen.Results will be shared through oral poster presentations and Q&A sessions.
-
Delayed on-demand treatment of hereditary angioedema attacks: patient perceptions and associated barriers: sandra christiansen maeve o’connor, Julie Ulloa, Shelley Danse, Viva Desai, Paul Audia, Paula Busse.Results will be shared through oral poster presentations and Q&A sessions.
-
Characteristics of hereditary angioedema attacks in long-term prophylactic users: Bob Genn, Viva Desai, Julie Ulloa, Shelly Danies, Paul Audia, Timothy Craig, Maeve Okonnor (presenter only).Results will be shared through oral poster presentations and Q&A sessions.
-
Treatment patterns for patients who require repeat on-demand treatment after recurrent HAE attacks: Constance KatelarisMichael Manning, Sally Van Kooten, Neil Malloy, Marcus Heckman, Julie Ulloa, William Lumley
-
Anxiety associated with refilling on-demand therapy for HAE attacks contributes to treatment delays and nontreatment. Daniel F. Soteres Anete S. GrumakSally Van Kooten, Neil Malloy, Marcus Heckman, Julie Ulloa, Autumn Burnett
-
Characteristics of the negative effects of delayed on-demand treatment of HAE attacks: Princess Ogbogu, Hilary Longhurst, Sally Van Kooten, Neil Malloy, Marcus Heckman, Julie Ulloa, Ricardo Zwiener
All poster presentations will be held on Friday, March 15th at 7:20pm EST in the Vetiver Room.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral small molecule protease inhibitors for diseases with significant unmet needs. KalVista disclosed positive Phase 3 data from his KONFIDENT trial of oral on-demand therapy sevetralstat in February 2024. The Company expects to submit a new drug application for sevetralstat to the U.S. FDA in the first half of 2024, and to file for regulatory approval in 2024. Additionally, KalVista’s oral factor XIIa inhibitor program represents a new generation of therapies that have the potential to further improve the treatment of people living with HAE and other diseases.
For more information about KalVista, please visit www.kalvista.com.
Forward-looking statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipates,” “intends,” and similar words. plan, “goal”, “seek”, “believe”, “project”, “estimate”, “expect”, “strategy”, “future”, “likely”, “may”, “Should”, “will” and similar references to future periods. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from our expectations. Examples of forward-looking statements include the timing and results of our communications with the FDA, our expectations regarding the safety and efficacy of our product candidates, the timing of clinical trials and their results, and our expectations regarding the timing and results of our communications with the FDA, the timing of our clinical trials and their results, and our expectations regarding regulatory authorities regarding sevetralstat and our other candidates. and our ability to obtain approvals. development, the success of efforts to commercialize sevetralstat, the ability of sevetralstat and other candidates in development to treat HAE or other diseases, and the future progress and success of our oral Factor XIIa program; Possibility of. For more information regarding the potential risk factors that could affect our business and financial results, please refer to our Annual Report on Form 10-K and Quarterly Reports on Form for the year ended April 30, 2023. These are detailed in our filings with the Trade Commission. 10-Q, and other reports we make from time to time to the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, made from time to time, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240308093167/ja/
contact address
Calvista Pharmaceuticals Co., Ltd.
Jarrod Aldom
Vice President of Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com
ryan baker
Director of Investor Relations
(617) 771-5001
